spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  diabetic macular edema 

 HSMN NewsFeed - 21 May 2024
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili(TM). Enters U.S. Ophthalmology Market
Biopharmaceuticals Generics Ophthalmology FDA
 HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 8 Aug 2022
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 29 Jun 2022
EYLEA(R) (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Apr 2022
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY(TM) (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Sep 2021
AbbVie and REGENXBIO Announce Eye Care Collaboration
Biopharmaceuticals Regenerative Medicine Ophthalmology
 HSMN NewsFeed - 21 Sep 2020
Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 17 Jul 2020
Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Jul 2020
LumiThera Closes Series C Round of Financing
Devices Ophthalmology Venture Capital
 HSMN NewsFeed - 18 Feb 2020
LumiThera to Expand Research into Diabetic Retinopathy for Valeda(R) Light Delivery System
Devices Ophthalmology
 HSMN NewsFeed - 13 Jan 2020
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Dec 2019
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 13 Aug 2019
FDA Approves EYLEA(R) (aflibercept) Injection Prefilled Syringe
Biopharmaceuticals Drug Delivery Ophthalmology FDA
 HSMN NewsFeed - 17 Jul 2019
U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 4 Jan 2019
Oculis Raises CHF15.5 Million in an Extension of its Series B Financing Round - Total Raised CHF35.5 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 25 Oct 2018
EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 24 Sep 2018
Oculis Appoints World-renowned Ophthalmology Specialist
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 19 Sep 2018
Oculis Elects Anthony Rosenberg and David A. Weber - Veterans of the Global Pharmaceutical and Eye-care Industries - to its Board of Directors
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 13 Aug 2018
Regeneron Provides Regulatory Update on EYLEA(R) (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 9 Jul 2018
Oculocare's Alleye(R) Receives FDA 510(k) Clearance for Monitoring Eyesight in AMD
Devices Diagnostics Ophthalmology FDA
 HSMN NewsFeed - 31 May 2018
Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in Spain
Biopharmaceuticals Ophthalmology Reimbursement
 HSMN NewsFeed - 19 Mar 2018
EYLEA(R) (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Feb 2018
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Jan 2018
Oculis Raises CHF20 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 11 Dec 2017
Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA(R) (aflibercept) Injection for Patients with Wet AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Nov 2017
Regeneron Provides Update on EYLEA(R) (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Feb 2017
Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in Italy
Biopharmaceuticals Ophthalmology Reimbursement
 HSMN NewsFeed - 29 Nov 2016
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Oct 2016
Ocular Therapeutix(TM) and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Oct 2016
FDA Grants Priority Review to Genentech’s Lucentis(R) (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 8 Aug 2016
Araim Pharmaceuticals Announces Appointment of Ferdinand C. Breedveld, M.D. as Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2016
pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
Devices Drug Delivery Orthopaedic
 HSMN NewsFeed - 23 Mar 2016
Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 2 Nov 2015
Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Oct 2015
Regeneron Announces EU Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 21 Oct 2015
Allegro Ophthalmics Names Scott Cooper as Chief Financial Officer and Vice President of Business Development and Mohamed Genead, MD, as Executive Medical Director
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 5 Aug 2015
Ohr Pharmaceutical Promotes Jason S. Slakter, MD to Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 22 Jul 2015
KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Jun 2015
EYLEA(R) (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 21 May 2015
Ampio Pharmaceuticals Announces Positive Study Results on Optina(TM) for the Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 22 Apr 2015
SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Feb 2015
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 25 Nov 2014
Eleven Biotherapeutics Announces Additional Financing of $20 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 17 Oct 2014
EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 29 Sep 2014
Allergan Announces FDA Approves Revised Indication for OZURDEX(R) (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology Drug Delivery FDA
 HSMN NewsFeed - 22 Sep 2014
Regeneron Announces EYLEA(R) (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 11 Aug 2014
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 30 Jun 2014
Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 23 Apr 2014
Kala Pharmaceuticals Announces $22.5 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 14 Apr 2014
Alimera Sciences Announces New PDUFA Date For ILUVIEN(R)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 18 Dec 2013
Regeneron Announces FDA Acceptance of EYLEA(R) (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 22 Nov 2013
EYLEA(R) (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 5 Sep 2013
ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 19 Feb 2013
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Dec 2012
EYLEA(R) (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 28 Nov 2012
Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Nov 2012
EYLEA(R) (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 14 Nov 2012
Alimera Sciences Names European Management Team
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 30 Aug 2012
Aerpio Therapeutics Completes $27 Million Series A Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 26 Jul 2012
FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology Endocrinology FDA
 HSMN NewsFeed - 21 Jun 2012
Ampio Reports Successful Type B Pre-IND Meeting with the FDA for its Drug Zertane(TM) to treat Premature Ejaculation (PE)
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 5 Jun 2012
Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in Portugal for the Treatment of Chronic Diabetic Macular Edema
Biopharmaceuticals Ophthalmology Drug Delivery Regulatory
 HSMN NewsFeed - 27 Apr 2012
IRIDEX Introduces Non-Invasive MicroPulse(TM) Therapy for Glaucoma
Devices Ophthalmology
 HSMN NewsFeed - 24 Apr 2012
ILUVIEN(R) Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema
Biopharmaceuticals Ophthalmology Drug Delivery Regulatory
 HSMN NewsFeed - 8 Mar 2012
Regeneron and Bayer Announce Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 12 Dec 2011
10-Year Study Demonstrates IRIDEX MicroPulse(TM) Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
Devices Ophthalmology
 HSMN NewsFeed - 18 Jul 2011
SARcode Bioscience Completes $44 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 Mar 2011
Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Feb 2011
Lucentis Phase III Study Meets Primary Endpoint for Improving Vision in Patients With Diabetic Macular Edema (DME)
Biopharmaceuticals Endocrinology Ophthalmology
 HSMN NewsFeed - 20 Dec 2010
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Dec 2010
Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 Jun 2010
Study Demonstrates that IRIDEX MicroPulse Laser Effectively Treats Eyes with Diabetic Macular Edema
Devices Ophthalmology
 HSMN NewsFeed - 10 Jun 2010
Quark Pharmaceuticals Closes $10 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Feb 2010
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Oct 2009
MacuSight(R) Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 21 Apr 2009
iScience Interventional, Inc. Closes $20.5 million Series F Financing
Devices Ophthalmology Venture Capital
 HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Feb 2009
pSivida Corp. Names Paul Ashton, Ph.D. President and Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 6 Nov 2008
MacuSight Appoints Gerald Wroblewski Vice President of Operations
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 17 Sep 2008
Merck & Co., Inc. Discontinues License and Research Collaboration Agreement with SurModics
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 3 Sep 2008
Neurotech Granted Fast Track Designations from the FDA for NT-501 in Two Indications - Retinitis Pigmentosa and Dry Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 7 Apr 2008
Quark Pharmaceuticals, Inc. Closes $27 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Mar 2008
DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
Biopharmaceuticals
 HSMN NewsFeed - 18 Mar 2008
Alimera Sciences Closes $30 Million in Series C Financing, Increasing Stake in Medidur(TM) FA
Biopharmaceuticals Venture Capital Ophthalmology
 HSMN NewsFeed - 20 Feb 2008
MacuSight Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 18 Jan 2008
Novagali Pharma Announces FDA Clearance of IND for US Clinical Trial of Nova63035 in Patients With Diabetic Macular Edema
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 12 Dec 2007
Fovea Pharmaceuticals Completes EUR30M Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Dec 2007
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Aug 2007
Bausch & Lomb Acquires Soothe(R) Emollient (Lubricant) Eye Drops from Alimera Sciences; Expands Product Line
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 18 Jul 2007
pSivida Strengthens its Position in Drug Delivery Sector
Biopharmaceuticals Drug Delivery Ophthalmology
 HSMN NewsFeed - 12 Jul 2007
TargeGen, Inc. Closes $40M Series 'D' Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Jun 2007
SurModics and Merck Enter Ophthalmic License and Research Collaboration Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 9 May 2007
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 May 2007
pSivida Announces Board Change
Biopharmaceuticals Ophthalmology Drug Delivery Personnel
 HSMN NewsFeed - 4 Apr 2007
pSivida Signs $165 Million(US) Collaborative Research and Licensing Agreement with Pfizer
Biopharmaceuticals Ophthalmology Drug Delivery Licensing
 HSMN NewsFeed - 27 Mar 2007
Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 29 Jan 2007
pSivida Announcement: RetisertTM Drug Implant Receives Product Specific Bill Code and Medicare Reimbursement Rate
Biopharmaceuticals Ophthalmology Reimbursement
 HSMN NewsFeed - 24 Jan 2007
pSivida appoints Boston based Managing Director
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 22 Jan 2007
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
Biopharmaceuticals Endocrinology Ophthalmology FDA
 HSMN NewsFeed - 26 Dec 2006
pSivida Enters Licensing Negotiations with Major Global Pharma for Drug Delivery Technologies
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 27 Nov 2006
Alimera Sciences Completes Second Tranche of Series B Financing, Receives $15.9 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 13 Nov 2006
Ruboxistaurin Reduced Vision Loss in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy in a New Study
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Nov 2006
MacuSight(TM) Appoints Brian C. Cunningham to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2006
Acuity Pharmaceuticals Appoints Denis O'Shaughnessy Senior Vice President of Clinical Development
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 18 Oct 2006
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 9 Oct 2006
First Patient Implanted in pSivida European Pancreatic Cancer Study
Devices Oncology
 HSMN NewsFeed - 25 Sep 2006
OptiMedica Announces Clinical Outcomes of 1,200 Patients Treated with PASCAL Method of Photocoagulation
Devices Ophthalmology
 HSMN NewsFeed - 9 Sep 2006
OptiMedica Receives ISO Certification and CE Mark for the PASCAL(R) Photocoagulator
Devices Ophthalmology Regulatory
 HSMN NewsFeed - 1 Jun 2006
Acuity Pharmaceuticals Reports Positive Initial Phase II Results for Bevasiranib (Cand5) in Wet AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 May 2006
pSivida Provides Update on BrachySil(TM) Liver Program: Expansion of Multicenter Clinical Trial
Biopharmacetuicals Oncology Drug Delivery
 HSMN NewsFeed - 10 May 2006
SurModics Licenses Ophthalmic Technology to Bausch & Lomb
Biopharmaceuticals Ophthalmology Licensing
Return to NewsFeed  

 Additional items found! 41

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 41 additional stories matching:
diabetic macular edema
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.